Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

Hevolution-AFAR New Investigator Awards expanded with $16 million grant

The American Federation for Aging Research (AFAR), is pleased to announce a $16 million expansion of the Hevolution-AFAR New Investigator Awards in Aging Biology and Geroscience Research, a grant program to enable early-career investigators with labs in the US and Canada to research healthspan-expanding therapeutics and treatments.

1 Dec 2023

New drug combination may improve treatment for rare nerve sheath tumors

Combining a pair of experimental drugs may help treat malignant peripheral nerve sheath tumors with fewer harmful side effects, according to preliminary animal studies led by investigators at the Johns Hopkins Kimmel Cancer Center and Johns Hopkins Drug Discovery.

1 Dec 2023

Genetic evidence suggests thiazide diuretics reduce kidney stone risk

Kidney stones affect nearly 10% of the global population. For more than three decades, thiazide diuretics, a common medication used for high blood pressure, have been the standard of care for kidney stone prevention because they reduce the excretion of urinary calcium.

30 Nov 2023

C-Path's TRxA and Celdara Medical announce MOU to identify and advance promising new therapeutics

Critical Path Institute's (C-Path) Translational Therapeutics Accelerator (TRxA) and Celdara Medical today announced the signing of a Memorandum of Understanding (MOU) aimed at identifying and advancing promising new therapeutics in areas of high unmet medical need.

29 Nov 2023

UK Biobank data opens door to new era of precision medicine

In a momentous landmark for medical research, UK Biobank has today [Thursday 30 November] unveiled incredible new data from whole genome sequencing of its half a million participants.

29 Nov 2023

Insilico Medicine hosts three webinars to unveil latest technology breakthroughs

Insilico Medicine ("Insilico"), an artificial intelligence (AI)-driven, clinical stage biotechnology company and leader in AI drug discovery platform technology, is hosting three webinars unveiling its latest technology breakthroughs Nov. 28-30, 2023.

29 Nov 2023

New heart organoid model could revolutionize drug development and toxicology studies

Heart disease kills 18 million people each year, but the development of new therapies faces a bottleneck: no physiological model of the entire human heart exists – so far.

28 Nov 2023

Unveiling a new cardiac myosin inhibitor through AI-driven virtual screening

Discovery of a novel cardiac-specific myosin modulator.

28 Nov 2023

CN Bio wins ‘Most Impactful Industry Collaboration of the Year’ at the OBN Awards 2023 for ongoing research with the FDA

CN Bio has received the ‘Most Impactful Industry Collaboration of the Year’ at the 2023 OBN Awards.

From CN-Bio 23 Nov 2023

Almirall and Absci partner to develop AI-designed therapeutics for dermatological diseases

Almirall S.A., a global biopharmaceutical company focused on medical dermatology, and Absci Corporation, a generative AI drug creation company, today announced a drug discovery partnership aimed to develop and commercialize AI-designed therapeutics to fight chronic and debilitating dermatological diseases. The partnership combines Absci’s Integrated Drug Creation™ platform with Almirall’s dermatological expertise with the goal of delivering life-changing medicines to patients, marking another step forward in AI drug creation.

20 Nov 2023

TACTIC project aims to uncover genetic causes of cancer and develop targeted therapies

Investigating the genetic causes of cancer and fighting them with new drugs: To this end, German Cancer Aid is funding the TACTIC project until 2028 with 11.8 million euros.

16 Nov 2023

Tackling Antimicrobial Resistance Together: A Conversation with Dr. Beverley Isherwood

An interview with Dr Beverley Isherwood.

16 Nov 2023

Circular extrachromosomal DNA identified as a potential target for new medulloblastoma therapies

A study of newly created databases of medulloblastoma has found that patients with tumors containing circular extrachromosomal DNA-;loops of DNA found outside of regular chromosomes-;are twice as likely to relapse and three times as likely to die within five years of diagnosis.

14 Nov 2023

Novel cancer immunotherapy compound degrades an enzyme found in cancer cells and T cells

Researchers in Purdue University's College of Pharmacy are leveraging the dual roles played by an enzyme found in both cancer cells and T cells to create a novel cancer immunotherapy compound.

14 Nov 2023

Introducing Luminescence 96: A Groundbreaking Advancement in Luminescence-Based Assays

With a vision to reenvision the lab and a passion for simplifying laboratory workflows with highly intuitive and functional designs, Byonoy launches Luminescence 96, further expanding its range of high-quality plate readers.

From Byonoy 14 Nov 2023

Discovery of two new enzymes offers easier ways to study and manufacture complex natural chemicals

Slumbering among thousands of bacterial strains in a collection of natural specimens at The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, several fragile vials held something unexpected, and possibly very useful.

13 Nov 2023

NanoSyrinx appoints Anthony Johnson as Non-Executive Director

Appointment of Big Pharma executive strengthens leadership team to drive ambitious growth strategy.

From NanoSyrinx 13 Nov 2023

Crown Bioscience launches large-scale organoid panel screening platform for accelerated preclinical oncology drug discovery

Crown Bioscience, a global contract research organization (CRO) and JSR Life Sciences company, today announced the launch of its ground-breaking service offering, OrganoidXploreTM.

13 Nov 2023

Open-science triumph: Crowdsourced initiative yields potent SARS-CoV-2 antivirals

In this study, researchers harnessed crowdsourcing and open science to develop new antivirals against SARS-CoV-2, focusing on its main protease, Mpro. Their approach led to the discovery of potent compounds, including one with high efficacy in cell lines and cross-reactivity against various COVID-19 variants, demonstrating the potential of collaborative and transparent drug discovery in tackling global health crises.

12 Nov 2023

Genetically engineered yeast cells produce natural plant product for schizophrenia treatment

An international team of researchers has demonstrated that genetically engineered yeast cells can produce the natural plant product alstonine, which has shown positive effects in treating schizophrenia.

10 Nov 2023

Drug Discovery News and Research

Further Reading

Hevolution-AFAR New Investigator Awards expanded with $16 million grant

New drug combination may improve treatment for rare nerve sheath tumors

Genetic evidence suggests thiazide diuretics reduce kidney stone risk

C-Path's TRxA and Celdara Medical announce MOU to identify and advance promising new therapeutics

UK Biobank data opens door to new era of precision medicine

Insilico Medicine hosts three webinars to unveil latest technology breakthroughs

New heart organoid model could revolutionize drug development and toxicology studies

Unveiling a new cardiac myosin inhibitor through AI-driven virtual screening

CN Bio wins ‘Most Impactful Industry Collaboration of the Year’ at the OBN Awards 2023 for ongoing research with the FDA

Almirall and Absci partner to develop AI-designed therapeutics for dermatological diseases

TACTIC project aims to uncover genetic causes of cancer and develop targeted therapies

Tackling Antimicrobial Resistance Together: A Conversation with Dr. Beverley Isherwood

Circular extrachromosomal DNA identified as a potential target for new medulloblastoma therapies

Novel cancer immunotherapy compound degrades an enzyme found in cancer cells and T cells

Introducing Luminescence 96: A Groundbreaking Advancement in Luminescence-Based Assays

Discovery of two new enzymes offers easier ways to study and manufacture complex natural chemicals

NanoSyrinx appoints Anthony Johnson as Non-Executive Director

Crown Bioscience launches large-scale organoid panel screening platform for accelerated preclinical oncology drug discovery

Open-science triumph: Crowdsourced initiative yields potent SARS-CoV-2 antivirals

Genetically engineered yeast cells produce natural plant product for schizophrenia treatment

Drug Discovery - Second Edition eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News